Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 3, 2021

Altru Health to deploy Deep Lens’ AI clinical trial matching solution

Altru Health System has entered a strategic alliance to adopt Deep Lens’ artificial-intelligence (AI)-based clinical trial matching solution, named VIPER, across its network.

Altru Health System has entered a strategic alliance to adopt Deep Lens’ artificial-intelligence (AI)-based clinical trial matching solution, named VIPER, across its network.

VIPER leverages cloud-based technology to facilitate, triage and fast-track the patient enrolment during the clinical trial recruitment process.

It is developed to improve efficiencies using automated screening and data management. With the solution, Altru expects more opportunities to take part in new precision medicine trials.

Altru Health System Research Program supervisor Ashlee Dagoberg said: “VIPER will not only assist in expanding patient access to trials, but the relationship with Deep Lens will allow us to broaden our clinical research programme.

“They will bring new sponsored trials to our system which in turn will allow our patients to participate in more precision medicine studies involving emerging new therapies.”

VIPER will be deployed directly into the Altru Health System’s electronic medical record EPIC and molecular data feeds – Foundation Medicine, Myriad Genetics, Tempus, Guardant360.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

The AI solution will also be integrated into the company’s pathology system EPIC Beaker. With VIPER, Altru aims to automatically detect eligible patients for clinical trials.

Altru expects that deploying VIPER into its network will enable all cancer patients across its network in various geographical areas to access any clinical trial for which they may be qualified.

Approximately more than 15,000 oncology trials are actively enrolling subjects, but participation is often as low as 3%, Altru noted.

Patient recruitment challenges such as limited trial site capacity and narrow study eligibility requirements have been identified. However, the participation rate in cancer trials has not improved significantly over time.

To help improve participation, VIPER automates the trial screening process and matches patients at the time of diagnosis to suitable trials. The solution incorporates and analyses tailored genomic data, electronic medical records and pathology data.

Last month, Oregon Oncology Specialists agreed to integrate a Deep Lens’ AI-based clinical trial screening platform.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU